Pharming Group N.V annual debt-to-ebitda ratio
2019
2020
2021
2022
2023
2025
Pharming Group N.V Debt-to-EBITDA Ratio Growth & History (PHAR)
Pharming Group N.V's debt-to-ebitda ratio was 0.52 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.52 | — | — |
| 2023 | 2023-12-31 | 16.75 | 15.37 | +1114.15% |
| 2022 | 2022-12-31 | 1.38 | 0.33 | +31.82% |
| 2021 | 2021-12-31 | 1.05 | 0.92 | +744.98% |
| 2020 | 2020-12-31 | 0.12 | 0.03 | +28.19% |
| 2019 | 2019-12-31 | 0.10 | — | — |
Pharming Group N.V quarterly debt-to-ebitda ratio
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.66 | — | — |
| Q1 2026 | 2026-03-31 | 2.66 | — | — |
Pharming Group N.V debt-to-ebitda ratio trends
Over the last five fiscal years, Pharming Group N.V's debt-to-ebitda ratio increased from 0.12 to 0.52, a change of 0.40. The latest reported quarter, Q2 2026, shows 2.66.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...